Clinical Trial Update: Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib [Phase 3]

View source ↗

Summary

Phase 3 trial assessing masitinib in gastrointestinal stromal tumors after progression on imatinib has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumors

Drugs mentioned

• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: COMPLETED